Articles tagged with Vaccine Development
Scientists at TSRI have developed a method to analyze the glycan shield on HIV's protective outer glycoprotein, enabling the creation of a 'fingerprint' to identify potential vaccine targets. The new method saves time and has revealed that the glycoprotein does not have as many holes as previously predicted.
A Phase 1 clinical trial found that a two-vaccine regimen against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers. The investigational vaccines used harmless viral vectors to deliver proteins of the Ebola virus, prompting an immune response.
Researchers at GW University have developed a new relative potency testing program for the Na-GST-1/Alhydrogel hookworm vaccine, showing it remains stable and immunogenic after five years of storage. This innovation aims to improve vaccine effectiveness in developing countries where hookworm infections are prevalent.
A study published in the Public Library of Science Pathogens found that Zika virus targets neuronal, lymph, joint, muscle and genital/urinary/reproductive tissues, persisting for at least 35 days. The research provides insights into the growth and distribution of the virus in human tissues.
A study published in AIMS Public Health estimates that the 1962 human cell strain breakthrough saved nearly 10 million lives and prevented over 4.5 billion cases of disease globally through vaccination. The development enabled vaccines to be produced safely, leading to widespread vaccination against multiple infections.
Researchers developed a new relative potency testing program to study the potency of vaccines for tropical diseases. The program found that the Na-GST-1/Alhydrogel Hookworm Vaccine was potent over 60 months of storage, with increased potency in humans living in endemic areas.
A new article recommends establishing an institute focused on developing vaccines of public health importance without commercial interest. The proposed institute will require collaboration among stakeholders from industry, government, academia, and private foundations.
Researchers have discovered a new class of compounds that kill adult and egg stages of the human whipworm, a parasite infecting 500 million people. These compounds could lead to effective treatments and vaccines for whipworm infections, which cause physical and mental damage.
The MIT-led project aims to standardize vaccine manufacturing at globally affordable costs by combining automation and reducing labor costs. The goal is to produce vaccines for less than 15 cents a dose, with the potential to make global vaccination more accessible.
In less than a year, researchers have developed multiple vaccine platforms providing robust protection against Zika virus challenge in animal models. However, safety considerations and unique challenges associated with the virus must be addressed in clinical development.
Researchers compared informed consent quality in clinical trials of a hookworm vaccine conducted in Brazil and the US. Despite differences in education and healthcare access, there were few statistically significant differences in consent quality between participants in urban and rural locations.
A Queensland-led team has developed an effective and economical Ebola treatment made with antibodies from horses, which could be used in the next outbreak. The post-exposure treatment is a cost-effective alternative to monoclonal antibodies, which require significant investment for scale-up and manufacture.
Researchers at Johns Hopkins Bloomberg School of Public Health identified a mechanism by which the chikungunya virus controls infection severity. The study found that all alphaviruses and coronaviruses may work in the same way, and that breaking a specific protein bond can prevent viral replication.
Researchers have developed a new method to produce stable poliovirus protein shells, which can be used as vaccines and do not require growing live viruses. The shells have been shown to induce high levels of protective antibodies in mice and rats.
A global partnership, CEPI, aims to create vaccines for emerging infectious diseases with a $460m initial investment from governments and foundations. The Coalition will target MERS-CoV, Lassa, and Nipah viruses, as well as Ebola and Zika, to develop safe and effective vaccines that can be deployed rapidly to contain outbreaks.
Researchers emphasize the need for continued study of Zika virus due to its serious complications and the importance of developing effective vaccines and treatments. Lessons learned from other arboviruses like West Nile and Chikungunya highlight the risks of fading interest in diseases that transition to endemicity.
Scientists have developed new HCV vaccination strategies using a model system, aiming to create durable and effective vaccines for all populations. The project, led by Professor Peter Simmonds, will focus on addressing the substantial societal problem of HCV infection.
Researchers at UTMB have developed an oral vaccine against salmonella that can be taken by mouth to protect against poisoning. The vaccine was shown to produce strong immunity in mice and holds promise for future use in humans.
Researchers at The University of Texas Medical Branch at Galveston have developed a novel chikungunya vaccine using an insect-specific virus that doesn't affect humans. The new vaccine elicits strong immune defenses and protects mice and nonhuman primates from disease when exposed to the chikungunya virus.
Researchers have identified two neutralizing antibodies against Zika virus that exclusively target the virus, demonstrating high specificity and protecting mice from infection. These antibodies, Z23 and Z3L1, block infection by targeting the virus' envelope protein, offering potential hope for preventative and treatment approaches.
Recent developments in dendritic cell vaccines and oncolytic immunotherapy have led to improved outcomes in melanoma patients. Various vaccine candidates are being developed and tested in clinical trials, offering new avenues for treating this malignancy.
Researchers developed a standardized approach to analyze full costs of cholera vaccines in developing countries, revealing significant variability in costs. The analysis showed vaccine delivery costs ranging from $0.36 to $6.32 per person vaccinated, with procurement costs varying between $0.29 and $29.70.
Researchers have created two compounds that work as potential vaccines against opioid overdoses, preventing the drugs from entering the central nervous system and inducing addiction. The vaccine candidates showed promising results in mouse tests, with vaccinated mice surviving overdose fatalities at higher rates than unvaccinated mice.
Researchers found that 2-dose HPV vaccine regimens for girls and boys aged 9-14 years had noninferior antibody responses compared to 3-dose regimens for adolescent girls and young women. The study suggests using a 2-dose schedule could improve adherence to HPV vaccination programs and reduce healthcare costs.
Portland State University has been awarded a $100,000 grant by the Bill & Melinda Gates Foundation to develop a new method for stabilizing stool samples. This technology could improve diagnosis and treatment of intestinal parasites in developing countries.
A human antibody that neutralizes Zika virus has been shown to reduce levels of the virus in placental and fetal tissues and decrease fetal disease in a mouse model of Zika infection. The findings suggest that this antibody could be developed to protect pregnant women and others from Zika-related complications.
The Walter Reed Army Institute of Research has begun a Phase 1 human clinical trial to test the safety and immunogenicity of the ZPIV vaccine, developed using an inactivated flavivirus vaccine platform. The trial involves 75 healthy adults and is part of the US Department of Defense response to the ongoing Zika virus outbreak.
New research from York University and Xi'an Jiaotong University finds that vaccinating against dengue fever can increase the spread of Zika. The study used mathematical modeling to investigate the effect of dengue vaccination on Zika outbreaks.
Researchers found that Th17 cells protect against the Trypanosoma cruzi parasite, which causes Chagas disease, by activating the immune system. This discovery offers a new approach to developing more protective vaccines for these diseases.
Scientists have identified thousands of previously unknown epitopes on the surface of cells, which could lead to a deeper understanding of the immune system and new avenues for therapies. The discovery of 'spliced' epitopes could provide new targets for immunotherapy and vaccine design.
A new study by Michigan State University researchers demonstrates that digital scans of a young child's fingerprint can be correctly recognized one year later, allowing for proper medical care. The technique has the potential to save millions of lives by tracking vaccination records and providing lifelong identity.
Researchers from UTMB have developed three new potential vaccines against the plague that protect animals from developing pneumonic plague as late as four to five months after vaccination. The vaccines were engineered by deleting and modifying genes in Yersinia pestis bacteria, resulting in safe vaccine candidates.
IDRI aims to develop a safe and effective Zika vaccine using RNA-based technology, which can be rapidly manufactured without requiring egg growth or bacteria cultivation. The institute plans to leverage the Zika virus's own machinery for expression of immunogenic proteins.
Researchers used satellite imagery and vaccination records to estimate population size and optimize vaccination coverage. The study showed that timing vaccination campaigns with predictable population peaks can improve coverage, especially in areas with limited access to health services.
Researchers at the University of Pittsburgh School of Medicine have developed two successful Zika vaccines that protect against neurological damage in newborn mice. The microneedle array vaccine showed significant protection, while the adenovirus-based vaccine was used as a proof-of-principle vaccine to test the envelope protein antigen.
Researchers have successfully developed new approaches to induce HIV-blocking antibodies in mice with human-like immune systems. The studies showed that a prime shot combined with booster shots of immunogens can activate precursor cells to produce neutralizing antibodies, paving the way for future clinical studies.
Researchers have developed a new approach to creating human vaccines against HIV using Kymouse, a genetically modified mouse that mimics human antibody responses. The study found that Kymouse can produce antibodies of the type needed for protection, suggesting ways to improve immunization regimes.
Researchers find that a widely available dengue vaccine could worsen the disease in some settings, particularly in low-transmission areas. The vaccine has shown to reduce illness and hospitalization by 20-30% in high-transmission countries but may increase these rates in locations with lower transmission.
A novel schistosomiasis vaccine called Sm14 Vaccine has reached phase II clinical studies, prioritized by the World Health Organization. The vaccine aims to prevent the parasite that causes the disease from installing in the patient's organism and causing damage.
Researchers cloned an epidemic strain of Zika virus, creating a model to test strategies for stopping the pandemic. The clone is used for developing a live but attenuated vaccine to create long-term immunity.
Three different investigational Zika virus vaccine platforms protect against infection and induce immune responses in rhesus macaques. The results suggest that each approach holds promise for designing an effective Zika vaccine.
Two vaccine candidates have shown complete protection against the Zika virus in rhesus monkeys, with no adverse effects observed. The findings, published in the journal Science, provide a promising lead for developing a safe and effective human vaccine to combat this mosquito-borne disease.
Researchers have successfully tested two Zika vaccine candidates in nonhuman primates, demonstrating robust protection against both Brazilian and Puerto Rican strains of the virus. The findings support the advancement of these vaccine candidates to human trials, with phase 1 clinical testing expected to begin later this year.
Researchers at Duke University Medical Center have discovered key immune differences that can help in the development of an effective HIV vaccine. The study found that HIV-infected individuals with broadly neutralizing antibodies had similar immune alterations as those with autoimmune disease.
Researchers have identified specific antibodies that protect against Zika infection in mice, targeting a region of the virus similar to other flaviviruses like Dengue and West Nile. These findings aim to optimize current vaccine strategies and develop new antibody-based therapeutics.
The National Institute of Allergy and Infectious Diseases (NIAID) has begun a Phase 1 study to evaluate the safety and efficacy of an experimental yellow fever vaccine developed by Bavarian Nordic. The trial will assess whether the investigational vaccine can prevent yellow fever virus infection and induce a strong immune response.
Researchers at McMaster University have developed a novel vaccine candidate, BD584, which shows promise in reducing chlamydial shedding and hydrosalpinx by 95% and 87.5%, respectively. The vaccine has the potential to be widely protective against all Chlamydia trachomatis strains, including those causing trachoma.
A new minimally invasive tissue sampling technique will help determine the cause of death in children, facilitating ways to save lives and improve health in vulnerable areas. The CHAMPS project aims to create a network of disease surveillance sites to address child mortality rates, which claim nearly 6 million lives annually.
A new study published in Nature demonstrates complete protection against the Zika virus in mice using two different vaccine candidates. The researchers showed that a single dose of either a DNA vaccine or a purified inactivated virus vaccine provides complete protection, similar to existing vaccines for other flaviviruses.
A new preclinical study suggests that an effective Zika vaccine is achievable. Two vaccine candidates were tested and found to be safe and protective against the virus in mice. The purified inactivated virus (PIV) vaccine is being developed and planned for human testing later this year.
A new software tool, RepeatAnalyzer, has been developed to track and catalogue short repeating sequences of bacterial DNA, improving scientists' ability to identify and understand bacterial strains. This technology could significantly accelerate vaccine development for tick-borne bacteria such as Anaplasma marginale.
Using drones to deliver vaccines in low- and middle-income countries could improve vaccination rates by up to 96% while producing significant cost savings. The technology has the potential to save $8.93 per dose and annual infrastructure costs of up to $60,000.
Researchers at Vanderbilt University Medical Center are recruiting volunteers for a clinical trial aimed at decoding the human immunome. The study, part of the Human Vaccines Project, will generate data on the genetic underpinnings of the immune system to guide next-generation vaccine development.
Lomonosov Moscow State University scientists have developed a new method to extract DNA from various organisms. This breakthrough could lead to the creation of preventive vaccines against infectious diseases, allergies, and cancers.
Researchers genetically engineered a Zika virus infectious cDNA clone, enabling rapid vaccine development and exploration of the virus's evolution and transmission. The study unlocks insights into why the Zika virus causes severe diseases and epidemics.
Researchers have developed zinc-oxide nanoparticles that can prevent the herpes simplex virus from entering cells and stimulate natural immunity to develop. The particles, called ZOTEN, work by attracting the virus and allowing immune cells to process it.
Researchers at the University of Copenhagen have created a general and user-friendly platform for developing effective vaccines. The technique mimics the structure of a virus, allowing it to trigger an immune response against diseases such as cancer, asthma, and allergies.
Global norovirus experts identify key gaps in knowledge and provide information to further vaccine development. The most efficient approach is developing a vaccine for young children, with the greatest impact at the global level.
Experts argue that good governance, long-term technology investment, and strong product management skills are essential to combat infectious outbreaks. The proposed global strategy aims to pool funds and coordinate efforts to develop effective countermeasures for these diseases.
An immunization regimen using two Ebola vaccine candidates was found to be safe and well-tolerated, inducing an immune response in healthy adult volunteers. The study's results suggest that the vaccines could provide durable protection against Ebola, which is essential for areas with intermittent outbreaks.